What is the primary treatment for MRSA and VRE infections?

Daptomycin is indeed used as a primary treatment for infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). It is a lipopeptide antibiotic that works by disrupting bacterial cell membrane function, leading to rapid bacterial cell death. Daptomycin is particularly effective against gram-positive organisms, including MRSA, and is often used in cases where traditional treatments like vancomycin are not effective or when there is concern for resistance, especially with VRE.

This makes it a pivotal option in treating serious infections caused by these resistant pathogens. While other antibiotics noted in the options, such as vancomycin, clindamycin, and linezolid, are effective against MRSA and some strains of Enterococcus, daptomycin has a unique spectrum and mechanism that makes it a superior choice in specific scenarios, particularly for VRE where other options may fail.

Vancomycin is traditionally a frontline therapy for MRSA infections; however, VRE poses a significant challenge where daptomycin may be utilized instead. Clindamycin and linezolid have their roles but may not be as effective in certain resistant-strain infections or in